Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadliesive polymeric diffusion environment and a barrier environment.
Type:
Application
Filed:
July 3, 2023
Publication date:
February 29, 2024
Applicant:
BioDelivery Sciences International, Inc.
Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.
Type:
Application
Filed:
August 30, 2023
Publication date:
February 29, 2024
Inventors:
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of pain, an autoimmune disorder, an autoinflammatory disorder, an inflammatory disorder, a central nervous system disorder, spinal cord injury, a metabolic disorder, a gastrointestinal disorder, a cardiovascular disorder, a fibrotic disorder, a respiratory disorder, a skin disorder, an allergic disorder, or cancer.
Abstract: Provided is a pharmaceutical formulation in the form of a softgel dosage form including a calcitonin gene-related peptide (CGRP) inhibitor, a lipophilic phase, and at least one lipophilic surfactant. Also provided is a method for increasing bioavailability of a calcitonin gene-related peptide (CGRP) inhibitor in a subject, including orally administering the pharmaceutical formulation to increase the bioavailability of the CGRP inhibitor in the subject.
Type:
Application
Filed:
December 16, 2021
Publication date:
February 29, 2024
Inventors:
Charles M. CONWAY, Gene M. DUBOWCHIK, Rajesh KUMAR
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Type:
Application
Filed:
June 27, 2023
Publication date:
February 29, 2024
Inventors:
Steven W. ANDREWS, Sean ARONOW, James F. Blake, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
Type:
Application
Filed:
October 25, 2023
Publication date:
February 29, 2024
Applicant:
INTRA-CELLULAR THERAPIES, INC.
Inventors:
Sharon MATES, Robert DAVIS, Kimberly VANOVER
Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.
Type:
Application
Filed:
October 18, 2023
Publication date:
February 29, 2024
Inventors:
Sarah Deborah CHIRNOMAS, Richard Walter GEDRICH, Ronald PECK, Ian Charles Anthony TAYLOR
Abstract: Disclosed herein are RNA methyltransferase inhibitors and methods of using and making the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of the RNA methyltransferase inhibitor and an effective amount of a DNA damaging agent to the subject.
Abstract: The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
Abstract: Disclosed are methods and compositions for treating cell proliferative diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that inhibits the biological activity of the autophagy related 4B cysteine peptidase (ATG4B) protein in conjunction with additional therapeutic agents or treatments.
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: Provided are cathepsin inhibitor compounds and pharmaceutically acceptable salts thereof, and combinations thereof, for use in the treatment or prophylaxis of viral disease in an animal.
Type:
Application
Filed:
March 26, 2021
Publication date:
February 29, 2024
Inventors:
Sina BAVARI, Christopher D. KANE, Andrew James PEAT, Veronica SOLOVEVA
Abstract: Liquid polymer pharmaceutical compositions with a biodegradable liquid polyester that has a carboxylic acid end group, a biocompatible solvent, and an active pharmaceutical agent are useful for administration into the body to provide extended long term release of the drug.
Type:
Application
Filed:
August 9, 2023
Publication date:
February 29, 2024
Inventors:
John Milton Downing, Vipin Saxena, John Middleton
Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
Abstract: Food, beverage and nutritional supplements containing microparticles containing stabilised CBD oil, and methods for the production thereof” Food, beverage and nutritional supplements that containing microparticles are described. The microparticles contain CBD oil stabilized in an acacia or inulin fibre or cyclodextrin matrix. Methods for the production of the compositions comprise making the microparticles by providing an oil-in-water microemulsion comprising CBD oil, water, acacia/inulin fibre and optionally maltodextrin or cyclodextrin, and freeze-drying the microemulsion to remove water and provide a preparation of dried microparticles. The dried microparticles comprise a dispersed phase of stabilized microdroplets of CBD oil disposed in a continuous solid matrix comprising acacia or inulin fibre. The preparation of microcapsules contains less than 10% free CBD oil and exhibit improved pharmacokinetics and bioavailability of CD.
Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.
Type:
Application
Filed:
July 21, 2023
Publication date:
February 29, 2024
Inventors:
Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
Abstract: Pharmaceutical compositions are provided containing psilocybin, which are designed for rapid dissolution properties and immediate or rapid release. The compositions are designed for targeted release by way of: (1) stomach release; or (2) mucosal release. The compositions can be used as pre-formulations for further tableting, encapsulation, or formulating into a sublingual dosage form for oral use, designed for rapid therapeutic onset. Particularly, the compositions overcome unfavourable formulation characteristics of psilocybin that cause drug release variability and problems for formulating into finished dosage forms. More particularly, psilocybin is formulated in a manner to overcome drug release variability thereby providing uniform potency and desirable bioavailability characteristics. The compositions may be used for inducing therapeutically beneficial behaviour change in subjects with a variety of psychiatric conditions.
Type:
Application
Filed:
August 10, 2023
Publication date:
February 29, 2024
Applicant:
Xpira Pharmaceuticals Inc.
Inventors:
Maria Vanesa Fernandez CID, Nicholas Jo Lic WONG
Abstract: Methods and compositions for increasing NAD levels in human subjects utilizing an effective amount of D-ribose and nicotinamide. The method and composition may also increase glutathione levels in the human subjects. The method and composition may also increase NAD levels and glutathione levels in the human subjects without causing redox unbalance in the subjects.
Abstract: The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and at least one of a first saccharide chain and a second saccharide chain linked to the aglycone core structure, wherein the saponin derivative comprises an aglycone core structure comprising an aldehyde functional group which has been transformed to a semicarbazone functional group. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention. In addition, the invention relates to a pharmaceutical combination comprising the first pharmaceutical composition of the invention and a second pharmaceutical composition comprising for example an ADC or a GalNAc-oligonucleotide conjugate.
Type:
Application
Filed:
September 9, 2021
Publication date:
February 29, 2024
Inventors:
Guy HERMANS, Ruben POSTEL, Helmus VAN DE LANGEMHEEN, Mazdak ASADIAN BIRJAND
Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Type:
Application
Filed:
October 24, 2023
Publication date:
February 29, 2024
Inventors:
Uli Christian BROEDL, Sreeraj MACHA, Maximilian von EYNATTEN, Hans-Juergen WOERLE
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.
Type:
Application
Filed:
July 17, 2023
Publication date:
February 29, 2024
Applicant:
The University of North Carolina at Chapel Hill
Abstract: The present invention relates to novel pharmaceutical combinations and compositions comprising sucralfate and magnesium alginate, a process for their preparation and the use of said compositions in therapy, in particular for the treatment and/or prevention of disorders of the upper gastro-intestinal tract.
Type:
Application
Filed:
December 30, 2021
Publication date:
February 29, 2024
Inventors:
Paolo COLOMBO, Carmelo SCARPIGNATO, Alessandra ROSSI
Abstract: The present disclosure relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions. In particular, the disclosure relates to use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions mediated by mature Nerve Growth Factor (NGF) or its precursor pro-Nerve Growth Factor (pro-NGF).
Abstract: Prophylaxis and treatment of patients susceptible to infection by coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is achieved using compositions including one or more inhibitors including sulfated glycans and/or highly negative charged compounds. The inhibitors bind to wild-type and variant spike glycoproteins (S-proteins or SGPs) of SARS-CoV-2, inhibiting fusion, entry, and infection of a host cell. The inhibitors can include pentosan polysulfate (PPS), mucopolysaccharide polysulfate (MPS), sulfated lactobionic acid, sulodexide, a defibrotide, 4-t-butylcalix[X] arene-p-sulfonic acid, or combinations thereof. The presence of additional sulfo groups in PPS and MPS contribute to the improved inhibitory activity of compositions with those sulfated glycans against COVID-19 compared with compositions containing heparin alone.
Type:
Application
Filed:
August 24, 2023
Publication date:
February 29, 2024
Applicant:
Rensselaer Polytechnic Institute
Inventors:
Robert John LINHARDT, Fuming ZHANG, Jawed FAREED, Walter JESKE
Abstract: The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
Type:
Application
Filed:
August 30, 2022
Publication date:
February 29, 2024
Applicant:
Ethicon, Inc.
Inventors:
Salim A. Ghodbane, Sridevi Dhanaraj, Brian Aitken
Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.
Type:
Application
Filed:
October 27, 2023
Publication date:
February 29, 2024
Applicant:
United Kingdom Research and Innovation
Inventors:
Carlos André Passos BASTOS, Jonathan Joseph POWELL, Nuno Jorge Rodrigues FARIA, Bradley Michael VIS
Abstract: Compositions and methods for the treatment of pruritic ani and anal fissures are described. The compositions include one or more of Calamine (95% zinc oxide and 0.5% ferric oxide) (USP) or zinc oxide (ZnO), aluminum hydroxide (Al(OH)3) or kaolin, glycerin, and menthol (or any compound which activates the menthol receptor (TRPM8)). The composition does not contain (or contains a limited amount, such as less than 10%) of a hydrocarbon-based pharmaceutical carrier such as petroleum jelly, white petrolatum, mineral oil, hard paraffin, soft paraffin, microcrystalline wax, or ceresine. Methods of treating pruritic ani and anal fissures by topical application(s) of the compositions to affected perianal or anal epidermis are also described.
Abstract: The present invention relates to fatty acid-modified polymer nanoparticles, and a use thereof. In the present invention, nanoparticles having embedded calcium carbonate crystals can be formed using a biocompatible polymer and an adipocyte-targeting ligand (a fatty acid) to minimize delivery to surrounding cells and tissues other than adipocytes and maximize the embedding of the nanoparticles into adipocytes. The nanoparticles according to the present invention can be produced as an injectable preparation, and can be applied to local lipolysis supplements or diet and beauty products that break down localized fat.
Abstract: Methods, formulations, and uses of a prophylactic nasal spray are provided. Many embodiments include nasal spray formulations including an microbicidal (e.g., virucidal) agent. Various embodiments include iodine, such as povidone iodine (PVP-I) as the microbicidal agent. Additional embodiments include methods to prophylactically treat an individual to prevent, mitigate, or otherwise limit a microbial infection.
Abstract: An analgesic component. The component is a +4-valent or +5-valent vanadium compound, and is selected from an inorganic vanadium compound or an organic vanadium compound, wherein the organic vanadium compound is selected from a vanadium complex or a chelate. A use of the +4-valent or +5-valent vanadium compound in preparation of an analgesic drug.
Abstract: The given invention is related to the field of medicine, namely to experimental research in oncology, and can be used to obtain a pharmaceutical agent for inhibiting the proliferation of HeLa cervical cancer cells. It entails the use of a metal powder obtained in a gaseous medium by means of an electric explosion of a wire made of low-carbon steel carried out with a specific energy of 7-18 kJ/g and a pulse duration of 1.2-2 ?s. The explosion is carried out inside a reactor that is pre-evacuated to a residual pressure of 10?2 Pa, and then filled with carbon monoxide to a pressure of 105 Pa at a gas circulation rate flow of 10 m/s. The products of the explosion deposited in a hopper are passivated in air for at least 48 hours. The resulting powder is extracted and mixed with a solution of the RPMI-1640 nutrient medium with L-glutamine, a pH of 7.2, in the proportion of the mass of the powder to the volume of the specified solution from 1:10 to 2.7:10.
Abstract: A method for producing CAR-M1 macrophages expressing a chimeric antigen receptor in vitro and in vivo includes using a conjugate of a non-viral gene delivery system and a chimeric antigen receptor gene. The CAR-M1 macrophages are produced in vivo by delivering genes encoding a chimeric antigen receptor and IFN-?, specifically to macrophages in the body, and thus does not require culturing and preparing an in-vitro cellular therapeutic agent, thus reducing the manufacturing costs of therapeutic agents. The CAR-M1 macrophages are a safer therapy since a non-viral vector is used, as compared to the production of CAR-M1 macrophages by gene delivery using a viral vector, and are a novel therapeutic candidate having the advantage of high anticancer efficiency for solid cancers, due to CAR-M1 macrophages in which intrinsic properties of macrophages infiltrating solid cancers and cancer cell phagocytosis are improved.
Type:
Application
Filed:
March 3, 2022
Publication date:
February 29, 2024
Inventors:
Byung Soo KIM, Mi Kyung KANG, Hee Ho PARK
Abstract: This disclosure provides compositions and methods for the treatment of inherited metabolic disorders in a subject. Provided herein are compositions and methods to treat Lysosomal Storage Diseases (LSD) in a subject using myeloid cells.
Type:
Application
Filed:
April 27, 2023
Publication date:
February 29, 2024
Inventors:
Ibrahim John DOMIAN, Panagiotis DOUVARAS, Christoph PATSCH, Chew-Li SOH, Stephanie A. FISHER, Maya SRINIVAS, Jing WANG, Carlos PALADINI, Ashley E. LEPACK
Abstract: The invention provides a modified T cell, or an isolated population of immune cells expressing a CXCR3 isoform selected from CXCR3A, CXCR3B, and CXCR3alt, and optionally, further expressing transgenes comprising an artificial T cell receptor, and/or a CXCR3 ligand, for use as a medicament. The invention also provides the methods to obtain said cells, or populations of cells from a plurality of immune cells derived from a human subject. The invention also relates to assessment of CXCR3 splice variants and its ligands CXCL9, CXCL10, and CXCL11 in muscle-invasive bladder cancer (MIBC) patients, to enable patients to be stratified for their predicted response to a chemotherapy drug treatment, or clinical outcome.
Type:
Application
Filed:
January 12, 2022
Publication date:
February 29, 2024
Applicant:
CHARITÉ-UNIVERSITÄTSMEDIZIN BERLIN
Inventors:
Hans Dieter VOLK, Michael SCHMÜCK-HENNERESSE, Tino VOLLMER, Petra REINKE, Stephan SCHLICKEISER
Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more compositions including one or more antigens) to treat a mammal (e.g., a human) having cancer are provided.
Type:
Application
Filed:
December 10, 2021
Publication date:
February 29, 2024
Inventors:
Richard G. Vile, Laura Evgin, Timothy J. Kottke
Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a modified TGF?RII expression.
Type:
Application
Filed:
May 18, 2023
Publication date:
February 29, 2024
Applicant:
PACT PHARMA, INC.
Inventors:
Charles W. TRAN, John D. Gagnon, Barbara Sennino, Stefanie Mandl-Cashman, Kyle Jacoby, William Lu, Michael Mayne Dubreuil, James S. Byers, III, Michal Mass, Alex Franzusoff
Abstract: The present invention relates to compositions and methods of generating modified hematopoietic stem or progenitor cells. One aspect of the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of decreasing expression of an endogenous gene or a portion thereof, wherein the endogenous gene encodes a polypeptide comprising an antigen domain targeted by a chimeric antigen receptor (CAR). Another aspect of the invention includes a method for generating a modified hematopoietic stem or progenitor cell. Also included are methods and pharmaceutical compositions comprising the modified cell for adoptive therapy and treating a condition, such as an autoimmune disease or cancer.
Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
Type:
Application
Filed:
November 7, 2023
Publication date:
February 29, 2024
Applicant:
Cellphire, Inc.
Inventors:
Keith Andrew MOSKOWITZ, Braden Carl ISHLER, William Matthew DICKERSON, Amber Nicole LEE, Shan XU
Abstract: A method for treating alopecia with a stem cell exosome, the alopecia includes androgenetic alopecia, seborrheic alopecia, and post-hair transplantation alopecia. An umbilical cord mesenchymal stem cell exosome has a significant curative effect on androgenetic alopecia, seborrheic alopecia, and post-hair transplantation alopecia.
Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are injected into the subject prenatally. The modified MSC may also express high levels von Willebrand factor protein.
Type:
Application
Filed:
March 31, 2023
Publication date:
February 29, 2024
Inventors:
Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Anthony Atala, Christopher B. Doering, H. Trent Spencer
Abstract: The present disclosure relates to a composition for skin improvement and a pharmaceutical composition for preventing or treating an inflammatory skin disease, the compositions including an umbilical cord-derived mesenchymal stem cell culture medium as an active ingredient. The compositions exhibit a wound relief, wrinkle improvement, regeneration, elasticity increase, moisturizing, barrier strengthening, anti-inflammatory or antioxidant effect, and thus can be effectively used as a cosmetic composition for skin improvement or a pharmaceutical composition for preventing or treating an inflammatory skin disease.
Type:
Application
Filed:
November 5, 2021
Publication date:
February 29, 2024
Applicant:
HANS PHARMA CO., LTD.
Inventors:
Na Eun LEE, Jung Tae LEE, Geun Young KIM, Jin Young KIM, Dong Wook KIM, Min Ji LEE, Ro Un LEE
Abstract: The present invention relates to a method for producing a culture medium-derived component or a crystallized culture medium using a PCA (Precipitation with Compressed Fluid Anti-solvent) drying process, a method for restoring chondrocytes using the culture medium-derived component or the crystallized culture medium prepared by way of the above method, a method for treating a subject having osteoarthritis by way of the method for restoring chondrocytes using the culture medium-derived component or the crystallized culture medium, a method for treating a subject having osteoarthritis using the culture medium-derived component or the crystallized culture medium, and the use of the culture medium-derived component or the crystallized culture medium for the treatment of osteoarthritis.
Type:
Application
Filed:
January 10, 2022
Publication date:
February 29, 2024
Applicant:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Nathaniel Suk-Yeon HWANG, Youn-Woo LEE, Heeseung KOH, Hee Jeong PARK, Jeong Uk KIM
Abstract: Methods are provided for the ex vivo reprogramming of microbiopsies of tissue such as from the skin, wherein the cells from the tissue are reverted to a state capable of extensive expansion in volume and when transplanted in vivo, of promoting scarless tissue regeneration at the site of administration.
Abstract: Molecular weight fractions of a conditioned medium of cultured amnion-derived multipotent progenitor cells, i.e., secretome fractions, and methods of processing a secretome such that it is separated into molecular weight fractions. Uses of the molecular weight secretome fractions to stimulate Schwann cell proliferation, promote neuroprotection, reduce retinal ganglion cell (RGC) loss, and reduce optic nerve inflammation in patients in need thereof.
Type:
Application
Filed:
November 16, 2021
Publication date:
February 29, 2024
Inventors:
Howard C. WESSEL, Larry R. BROWN, Ziv Z. KIRSHNER
Abstract: Provided herein is technology relating to preventing and treating gastrointestinal dysbiosis and particularly, but not exclusively, to compositions, methods, systems, and kits for treating and/or preventing Clostridioides difficile infection in an organism.
Abstract: Described are compositions and methods relating to layered granules comprising a core surrounded by a coating layer containing bioactive agents distributed within a protectant matrix, wherein the protectant matrix includes at least one polyhydroxy compound and at least one phosphate compound. The core and the protectant matrix are water soluble and fast-dissolving.
Type:
Application
Filed:
October 6, 2021
Publication date:
February 29, 2024
Inventors:
Nathaniel T Becker, Samuel A Maurer, Jared Sindelar, Henricus Jacobus Cornelis Gommeren, Ashwin Bala